Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2679

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1
Chunk 2679
---
 were to cease coverage of us or fail to regularly publish reports on it, our common stock and warrants
could lose visibility in the financial markets, which in turn could cause the price or trading volume of our common stock and warrants
to decline.

Future
issuances of debt securities and equity securities may adversely affect us, including the market price of our common stock and warrants
and may be dilutive to existing stockholders.

In
the future, we may incur debt or issue equity-ranking senior to our common stock. Those securities will generally have priority upon
liquidation. Such securities also may be governed by an indenture or other instrument containing covenants restricting our operating
flexibility. Additionally, any convertible or exchangeable securities that we issue in the future may have rights, preferences and privileges
more favorable than those of our common stock. Because our decision to issue debt or equity in the future will depend on market conditions
and other factors beyond our control, we cannot predict or estimate the amount, timing, nature or success of our future capital raising
efforts. As a result, future capital raising efforts may reduce the market price of our common stock and warrants and be dilutive to
existing stockholders.

There
can be no assurance that we will be able to comply with the continued listing standards of Nasdaq. Our failure to meet the continued
listing requirements of Nasdaq could result in a delisting of our common stock and warrants.

Following
the Business Combination, our common stock and warrants (other than warrants issued to Second Street Capital, LLC (the “Second
Street Warrants”)) were listed on Nasdaq under the symbols “OCEA” and “OCEAW,” respectively. If we are
not able to comply with the continued listing standard of Nasdaq, we and our stockholders could face significant material adverse consequences
including, but not limited to:

    ●
    a
    limited availability of market quotations for our securities;

    ●
    reduced
    liquidity for our securities;

    ●
    a
    determination that our common stock is a “penny stock,” which will require brokers trading in our common stock to adhere
    to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common
    stock;

    ●
    a
    limited amount of analyst coverage; and

    ●
    a
    decreased ability to issue additional securities or obtain additional financing in the future.

128

The
National Securities Markets Improvement